2022-501354-10-01招募中3 期
A Phase 3 randomized, placebo-controlled, double-blind, parallel-group program to evaluate efficacy and safety of filgotinib in adult subjects with active axial spondyloarthritis
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 487
- 试验地点
- 109
- 主要终点
- To compare the efficacy of filgotinib 200 mg versus placebo at week 16 on achieving ASAS40 response (Y/N)
研究概览
简要总结
To compare the efficacy of filgotinib 200 mg versus placebo on signs and symptoms
研究设计
- 分配方式
- Randomized
- 主要目的
- Dose de-escalation period
- 盲法
- Double (Analyst, Carer, Subject, Investigator, Monitor)
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- •Ambulatory female or male subjects >=18 years of age, on the date of signing the informed consent form (ICF)
- •Have an established diagnosis of axSpA by a rheumatologist (or other specialist with expertise in diagnosing axSpA)
- •Study A (r-axSpA): Meet Assessment of SpondyloArthritis International Society (ASAS) classification criteria with radiographic sacroiliitis on X-ray as follows: a. History of back pain >=12 weeks and age at onset of back pain <45 years, AND b. Have radiographic bilateral grade 2-4 sacroiliitis or unilateral grade 3-4 sacroiliitis, based on New York grading system, confirmed by central reading. Historical radiographs up to 6 months old are considered appropriate if they are accepted by the central reader. Otherwise, a new radiograph will be obtained during the screening period, AND c. >=1 spondyloarthritis (SpA) feature.
- •Study B (nr- axSpA): Meet ASAS classification criteria without radiographic sacroiliitis on X-ray as follows: a. History of back pain >= 12 weeks and age at onset of back pain <45 years, AND b. No radiographic bilateral grade 2-4 sacroiliitis or unilateral grade 3-4 sacroiliitis, AND c. Presence of sacroiliitis on MRI (based on central reading) and at least 1 SpA feature* or when positive for human leukocyte antigen (HLA)-B27: having at least 2 SpA features*, AND d. Have objective signs of inflammation, by sacroiliitis on MRI or elevated CRP *SpA features: inflammatory back pain, arthritis, enthesitis, uveitis, dactylitis, psoriasis, Crohn’s/colitis, good response to NSAIDs, family history for SpA, HLA-B27, elevated CRP.
- •Have active axSpA at screening and Day 1 defined by: • Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) >=4 (numeric rating scale [NRS] 0-10), AND • Spinal pain score >=4 (0-10 NRS) (based on BASDAI question 2)
- •Have a history of inadequate response to >=2 NSAIDs at the maximum dose of NSAIDs used in axSpA for >=2 weeks each (a total duration of NSAID trial >=4 weeks) or intolerance to >=2 NSAIDs for the treatment of axSpA
- •Subjects who are bDMARD(s) experienced; defined as below. - Subjects designated as bDMARD(s)-IR must have received not more than 2 bDMARD(s), that was/were administered in accordance with its/their labeling and discontinued due to: o Non-response (primary or secondary) after a minimum treatment of 12 weeks, and /or o Intolerance (defined as having experienced an adverse reaction [e.g. an infusion/injection reaction, an infection, a laboratory test change, etc] irrespective of treatment duration) - Subjects designated as bDMARD(s) non-IR have previously received bDMARD(s) and have discontinued these due to other reasons than non-response or intolerance (e.g. economic reasons, treatment as part of a clinical study, other, or unknown).
- •If continuing conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) during the study, subjects are permitted to use only a maximum of 2 csDMARDs and must have been on this treatment for >=12 weeks prior to screening, with a stable dose and route of administration (defined as no change in prescription) for >4 weeks prior to Day
- •In addition, methotrexate (MTX) use may not be combined with leflunomide during the study
排除标准
- •Prior exposure to a Janus kinase inhibitor, investigational or approved, at any time, including filgotinib.
- •Have undergone surgical treatments for peripheral manifestation of axSpA, including synovectomy or arthroplasty, or major surgery (requiring regional block or general anesthesia) <=12 weeks prior to Day 1 or planned major surgery during the study
- •Have a diagnosis of any generalized musculoskeletal disorder, e.g. generalized osteoarthritis, or systemic inflammatory condition other than axSpA such as, but not limited to, gout, rheumatoid arthritis, juvenile chronic arthritis, psoriatic arthritis (PsA), reactive arthritis, SAPHO (Synovitis, Acne, Pustulosis, Hyperostosis, Osteitis) Syndrome, systemic lupus erythematosus, systemic vasculitis, scleroderma, inflammatory myopathy, mixed connective tissue disease, fibromyalgia, post-acute coronavirus 19 (COVID-19) syndrome, and any overlapping syndrome. Note: Prior history of reactive or other types of inflammatory arthritis is permitted if there is documentation of change in diagnosis to axSpA or additional diagnosis of axSpA.
- •Have active Crohn's disease (CD) or active ulcerative colitis (UC). Note: subjects may be enrolled if they have had a history of inflammatory bowel disease (IBD), including CD and UC, but have had no exacerbation within 6 months prior to Day 1, and, if currently on treatment, must be on stable treatment for >=6 months prior to Day 1 and this treatment should be allowed per protocol.
- •Subject has a history of malignancy or myelo- or lymphoproliferative disorder, including NMSC, excised and curatively treated non-metastatic basal cell carcinoma, squamous cell carcinoma of the skin, or in situ uterine cervical carcinoma within the past 5 years prior to screening.
- •Active autoimmune disease other than those listed above, that would interfere with assessment of study parameters or increase risk to the subject by participating in the study (e.g. uncontrolled uveitis, uncontrolled thyroiditis, transverse myelitis, current peptic ulcer disease or prior history of severe diverticulitis [i.e. requiring hospitalization] or previous gastrointestinal perforation), per judgment of investigator
- •History of opportunistic infection, or immunodeficiency syndrome, which would put the subject at risk, as per investigator judgment
- •Subject has any other condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject (e.g. compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments. For subjects at increased risk of major cardiovascular problems (such as heart attack or stroke), those who smoke or have done so for a long time in the past (>10 pack-years) and those at increased risk of cancer, the investigator should carefully consider if participation is in the best interest of the subject.
- •Active infection that is clinically significant, as per judgment of the investigator, or history of a serious infection (requiring hospitalization or systemic antibiotics) within 12 weeks prior to screening.
- •Contraindication to MRI or any condition that would interfere with the ability to perform an MRI
- •Use of any opioid analgesic at average daily doses >30 mg/day of morphine (or equivalent) or use of unstable doses of any opioid analgesic <=2 weeks prior to Day 1
- •Use of any of the following systemic immunomodulating therapies <= 4 weeks prior to Day 1, including, but not limited to: 6-mercaptopurine, azathioprine, cyclosporine or other calcineurin inhibitors (e.g. sirolimus, tacrolimus), MTX if being discontinued, mycophenolate, antimalarials (e.g. hydroxychloroquine, chloroquine) if being discontinued, or sulfasalazine if being discontinued
- •Complete spinal ankylosis defined as the presence of consecutive bridging syndesmophytes in >=5 segments on the lateral radiograph (assessed by the central reader)
结局指标
主要结局
To compare the efficacy of filgotinib 200 mg versus placebo at week 16 on achieving ASAS40 response (Y/N)
To compare the efficacy of filgotinib 200 mg versus placebo at week 16 on achieving ASAS40 response (Y/N)
次要结局
- To compare the efficacy of filgotinib 200 mg versus placebo at week 16 on change from baseline in Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDASCRP)
- To compare the efficacy of filgotinib 200 mg versus placebo at week 16 on change from baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) magnetic resonance imaging (MRI) score of sacroiliac joints (SIJs)
- To compare the efficacy of filgotinib 200 mg versus placebo at week 16 on change from baseline in Bath Ankylosing Spondylitis Functional Index (BASFI)
- To compare the efficacy of filgotinib 200 mg versus placebo at week 16 on change from baseline in Ankylosing Spondylitis Quality of Life (ASQoL)
- To compare the efficacy of filgotinib 200 mg versus placebo at week 16 on change from baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI) (linear score)
- To compare the efficacy of filgotinib 200 mg versus placebo at week 16 on frequency and severity of treatment-emergent adverse events (TEAEs), treatment-emergent serious adverse events (SAEs), and TEAEs leading to treatment discontinuation
研究者
Lien Gheyle
Scientific
Galapagos
研究点 (109)
Loading locations...
相似试验
已完成
3 期
Ertugliflozin Pediatric StudyType 2 Diabetes Mellitus2022-501085-21-00Merck Sharp & Dohme LLC20
招募中
2 期
A study to investigate the safety and efficacy of infigratinib compared with placebo in infants and young children with achondroplasiaAchondroplasia2024-518072-31-00Qed Therapeutics Inc.6
招募中
3 期
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) ( PREVAIL )2024-519345-30-00Biogen Idec Research Limited201
进行中（未招募）
3 期
Efficacy and Safety of LP-003 Injection in Patients With Moderate to Severe Seasonal Allergic RhinitisNCT07291284Longbio Pharma546
招募中
3 期
Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant IR Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor DeficiencyNCT07266805Pharvaris Netherlands B.V.32